[SY7-5] Roles of HDAC1 and HDAC3 as therapeutic targets against myeloma cells
Professional Experience and Education
2007 M.D., Tokushima University Medical School, Japan
2007-2009 Clinical Resident, Tokushima Prefectural Central Hospital, Japan
2009-2014 Clinical Fellow in Department of Hematology, Tokushima University Hospital, Japan
2014 Ph.D. in Medical Sciences, Tokushima University Graduate School of Medical Sciences, Japan
2014-2017 Postdoctoral Research Fellow, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, USA
2017- Research Associate, Department of Hematology, Tokushima University Hospital, Japan
Awards
2013 ASH Abstract Achievement Award
2017 Japan Leukemia Research Fund Special Young Award
Research Interest
Cancer development and progression in hematological malignancies
2007 M.D., Tokushima University Medical School, Japan
2007-2009 Clinical Resident, Tokushima Prefectural Central Hospital, Japan
2009-2014 Clinical Fellow in Department of Hematology, Tokushima University Hospital, Japan
2014 Ph.D. in Medical Sciences, Tokushima University Graduate School of Medical Sciences, Japan
2014-2017 Postdoctoral Research Fellow, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, USA
2017- Research Associate, Department of Hematology, Tokushima University Hospital, Japan
Awards
2013 ASH Abstract Achievement Award
2017 Japan Leukemia Research Fund Special Young Award
Research Interest
Cancer development and progression in hematological malignancies
Abstract password authentication.
Password is written on a program and abstract book.